TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25240532

Group type: EXPERIMENTAL
Intervention: Canakinumab 0.1 mg/kg
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Canakinumab 0.3 mg/kg
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Canakinumab 1.5 mg/kg
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Canakinumab 10 mg/kg
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 22773198

Group type: EXPERIMENTAL
Intervention: Hybrid electric vehicle with artificially generated sound (VSP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hybrid electric vehicle without artificially generated sound
Number of subjects: 14

Group type: COMPARATOR
Intervention: Internal combustion engine vehicle (ICE)
Number of subjects: 14
Study: 20880172

Group type: EXPERIMENTAL
Intervention: Magnifying endoscopy with narrow-band imaging (ME-NBI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Indigocarmine chromoendoscopy (ICC)
Number of subjects: 110
Study: 17441321

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15794387

Group type: EXPERIMENTAL
Intervention: Oral pirfenidone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 12485553

Group type: EXPERIMENTAL
Intervention: Intention to treat (ITT) analysis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Excluded subjects categories
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ITT analysis participant inclusion
Number of subjects: 100
Study: 11504982

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 31
Study: 9988364

Group type: EXPERIMENTAL
Intervention: ipsapirone (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 8156064

Group type: EXPERIMENTAL
Intervention: Nonswimming exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 30982271

Group type: EXPERIMENTAL
Intervention: Exposed group (PCB contamination)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reference group (no PCB exposure)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exposed group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 60
Study: 29153975

Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy (EAT) withdrawn after 72 hours of apyrexia plus clinical recovery.
Number of subjects: 157

Group type: COMPARATOR
Intervention: Empirical antimicrobial therapy (EAT) withdrawn when neutrophil count was 0.5 x 10^9 cells per L or higher.
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Experimental group (EAT) adverse events reported: 341
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (EAT) adverse events reported: 295
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Severe adverse events in experimental group: 18
Number of subjects: 157

Group type: COMPARATOR
Intervention: Severe adverse events in control group: 38
Number of subjects: 157
Study: 25393038

Group type: EXPERIMENTAL
Intervention: Subconjunctival Bevacizumab (1.25 mg/0.05 mL)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham treatment (Control group)
Number of subjects: 46
Study: 23689809

Group type: EXPERIMENTAL
Intervention: Metronidazole (15 to 20 mg/kg per day for 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21339653

Group type: EXPERIMENTAL
Intervention: Nitrous oxide ‐ Isoflurane anesthesia (Nitrous oxide‐based group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Isoflurane anesthesia (Nitrous oxide‐free group)
Number of subjects: 116
Study: 19229497

Group type: EXPERIMENTAL
Intervention: CBT SL-5 lotion (containing cell-free culture supernatant of E. faecalis SL-5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 0
Study: 16536664

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Self-help manual only (SH)
Number of subjects: 90
Study: 14642690

Group type: EXPERIMENTAL
Intervention: N‐BNP group (GP received the N‐BNP result)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (GP did not receive the N‐BNP result)
Number of subjects: 305
Study: 11140073

Group type: EXPERIMENTAL
Intervention: Computer-based support and educational group for 5 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual modes of support and communication (Control)
Number of subjects: 30
Study: 11327445

Group type: EXPERIMENTAL
Intervention: Fozivudine tidoxil 1200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fozivudine tidoxil 800 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fozivudine tidoxil 400 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8255556

Group type: EXPERIMENTAL
Intervention: Amphetamine administration (oral and intramuscular)
Number of subjects: 0
Study: 3518724

Group type: EXPERIMENTAL
Intervention: Ibopamine (200-300 mg single oral dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg t.i.d. for 15 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg t.i.d. long-term treatment for 6 months)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30742244

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α treatment (group B)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) and sulfasalazine (SSZ) (group A)
Number of subjects: 133
Study: 29880356

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 μg/d)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 26762128

Group type: EXPERIMENTAL
Intervention: Culturally adaptive storytelling method intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 23937217

Group type: EXPERIMENTAL
Intervention: Calibration mapping from perceptual units to action units during throwing and extended reaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Action-specific approach to calibration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General purpose perception approach
Number of subjects: 0
Study: 22554931

Group type: EXPERIMENTAL
Intervention: B vitamins (2 mg folic acid, 25 mg vitamin B(6), and 500 μg vitamin B(12))
Number of subjects: 8164
Study: 20851549

Group type: EXPERIMENTAL
Intervention: 30-min infusion of imipenem/cilastatin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3-h infusion of imipenem/cilastatin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30-min infusion of meropenem
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3-h infusion of meropenem
Number of subjects: 18
Study: 17625106

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 16304444

Group type: COMPARATOR
Intervention: dilute formocresol
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: calcium hydroxide
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: ferric sulfate
Number of subjects: 107
Study: 12887823

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of Ramipril and Losartan
Number of subjects: 96
Study: 10457535

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7555614

Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1741645

Group type: EXPERIMENTAL
Intervention: Pancreatic resection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonoperative peritoneal lavage
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 6753500

Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 6740281

Group type: EXPERIMENTAL
Intervention: Duck embryo rabies vaccine (DEV), administered according to the prescribed schedule (14 initial inoculations and 3 boosters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duck embryo rabies vaccine (DEV)
Number of subjects: 0
Study: 31560051

Group type: EXPERIMENTAL
Intervention: Oral Vancomycin (OVP) 125 mg once daily for 5 days post-systemic antibiotics
Number of subjects: 100

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral Vancomycin (OVP)
Number of subjects: 100
Study: 30465358

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide in combination with 2% chlorhexidine gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Calcium hydroxide alone)
Number of subjects: 60
Study: 26698636

Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 7072

Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 7072
Study: 24794368

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (4 mg/kg/d for 2 weeks) and oral prednisolone (2 mg/kg/d for 2 weeks) followed by a tapering protocol for 9 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone and oral prednisolone
Number of subjects: 140
Study: 22849962

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 71

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 71
Study: 20627618

Group type: EXPERIMENTAL
Intervention: Cash reimbursement after each study visit (maximum possible = $425 over 12 weeks)
Number of subjects: 70
Study: 18638006

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day plus tadalafil 20 mg/day
Number of subjects: 30
Study: 15988786

Group type: EXPERIMENTAL
Intervention: Tensionless vaginal tape (TVT)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Intravaginal slingplasty (IVS)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Suprapubic arc procedure (SPARC)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 182
Study: 11211570

Group type: EXPERIMENTAL
Intervention: Yogic practices for the first five months of the course
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no yogic exercises during the first five months)
Number of subjects: 54
Study: 9662676

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 235

Group type: COMPARATOR
Intervention: Structured exercise program
Number of subjects: 235
Study: 7838778

Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonrandomized observational studies
Number of subjects: 0
Study: 2900410

Group type: EXPERIMENTAL
Intervention: Recorded therapeutic suggestions during general anaesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Blank tape (control)
Number of subjects: 39
Study: 30271132

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 43

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 43
Study: 27262892

Group type: EXPERIMENTAL
Intervention: Exercise therapy of the involved shoulder for 10 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Exercise therapy of the uninvolved shoulder for 10 weeks (Control group)
Number of subjects: 99
Study: 25249453

Group type: EXPERIMENTAL
Intervention: Free glasses provided in class
Number of subjects: 3177

Group type: EXPERIMENTAL
Intervention: Vouchers for free glasses at a local facility
Number of subjects: 3177

Group type: COMPARATOR
Intervention: Prescription for glasses only (control group)
Number of subjects: 3177
Study: 22386563

Group type: EXPERIMENTAL
Intervention: Combined criteria of LMVD and CT
Number of subjects: 94

Group type: COMPARATOR
Intervention: CT only
Number of subjects: 94
Study: 20334449

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy for secondary prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized antithrombotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0
Study: 16963726

Group type: EXPERIMENTAL
Intervention: Physical activity and dietary intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Engagement strategies (bilingual staff, culturally adapted materials)
Number of subjects: 200
Study: 16131701

Group type: EXPERIMENTAL
Intervention: Normal midsole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hard midsole
Number of subjects: 9

Group type: COMPARATOR
Intervention: Soft midsole
Number of subjects: 9
Study: 12243609

Group type: EXPERIMENTAL
Intervention: Selective serotonin-reuptake inhibitors (SSRIs)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 200
Study: 10030188

Group type: EXPERIMENTAL
Intervention: Systemic family nursing intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Regular services (Control)
Number of subjects: 198
Study: 8565089

Group type: EXPERIMENTAL
Intervention: 6-month short-course chemotherapy
Number of subjects: 287
Study: 2614634

Group type: EXPERIMENTAL
Intervention: Gore‐Tex periodontal material, held in place by sling sutures of expanded polytetrafluoroethylene (test site)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard treatment without Gore‐Tex material (control site)
Number of subjects: 12
Study: 775275

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 40
Study: 30879358

Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 305
Study: 29785873

Group type: EXPERIMENTAL
Intervention: Positive momentum condition (coming back from 1-7 to 7-7)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Negative momentum condition (opponent coming back from 7-1 to 7-7)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Time-out with no specific instructions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Time-out with task (mastery-approach - MAp) instructions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Time-out in negative momentum condition
Number of subjects: 80
Study: 26850040

Group type: EXPERIMENTAL
Intervention: weight loss via a healthful, guidelines‐based diet and exercise regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: wait‐list control
Number of subjects: 40
Study: 24194532

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT) for 2 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT)
Number of subjects: 80
Study: 24568070

Group type: EXPERIMENTAL
Intervention: Multidimensional Body Image Scale (MBIS) - 46 items
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Multidimensional Body Image Scale (MBIS) - 62 items
Number of subjects: 671
Study: 20576665

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 17980093

Group type: EXPERIMENTAL
Intervention: Combined 0.5% moxifloxacin and 0.1% dexamethasone formulation (Vigadexa)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional dosing with 0.5% moxifloxacin (Vigamox) and 0.1% dexamethasone (Maxidex)
Number of subjects: 139
Study: 15814546

Group type: EXPERIMENTAL
Intervention: Ganciclovir prophylaxis
Number of subjects: 205

Group type: COMPARATOR
Intervention: Aciclovir prophylaxis
Number of subjects: 205

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 205

Group type: COMPARATOR
Intervention: No prophylaxis or aciclovir alone
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Tacrolimus and cyclosporin-ME
Number of subjects: 205
Study: 11943521

Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 210

Group type: COMPARATOR
Intervention: Integrated epidural-general anesthesia
Number of subjects: 210

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 210
Study: 10084367

Group type: EXPERIMENTAL
Intervention: Supervised exercise training 2 times per week
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (n=23)
Number of subjects: 58
Study: 7595165

Group type: EXPERIMENTAL
Intervention: Cambridge 330 kcal day‐1 diet during the first 12 weeks followed by a well balanced hypocaloric diet (1600 kcal day‐1) with 220 kcal from two sachets of Cambridge diet (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cambridge 330 kcal day‐1 diet during the first 12 weeks followed by the same energy provided by the same principal diet (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups after 64-week treatment period
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: VLCD period
Number of subjects: 60
Study: 2147859

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 25-50 mg/day + ethinyl-estradiol (EE) 20-30 micrograms/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone (SPL) 100-200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPL + bromocriptine (2.5-5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) alone or associated with tamoxifen (100 mg + 100 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiandrogens in advanced prostatic carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiandrogens combined with surgical or medical castration (LH-RH analogues)
Number of subjects: 0
Study: 458893

Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (200 ml/m2/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma protein derivative (Plasmanate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma
Number of subjects: 20
Study: 31454713

Group type: EXPERIMENTAL
Intervention: Photodynamic inactivation (PDI) applied twice a week for four weeks using a GaA1As diode laser at 660 nm, 100 mW power, and 28 J/cm2 energy density.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nystatin (NST) oral suspension 100,000 IU used four times daily for 15 days.
Number of subjects: 36
Study: 28857709

Group type: EXPERIMENTAL
Intervention: Refurbishing (n=85; 67 AM, 18 RC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (n=89; 59 AM, 30 RC)
Number of subjects: 34
Study: 25791325

Group type: EXPERIMENTAL
Intervention: Fluoride varnish + CO2 laser (FV + CO2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonfluoride placebo varnish (PV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonfluoride placebo varnish + CO2 laser (PV + CO2)
Number of subjects: 14
Study: 24132190

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (in patients with prior MI)
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Warfarin (in patients with prior MI)
Number of subjects: 14264
Study: 21447050

Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sleep diaries
Number of subjects: 54
Study: 19359647

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering treatment (Perindopril)
Number of subjects: 6105
Study: 17296397

Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin-A
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 150 U botulinum toxin-A
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sedation-free procedure
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall procedure
Number of subjects: 27
Study: 15362317

Group type: EXPERIMENTAL
Intervention: Protective headgear
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Mouthguards
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (no protective equipment)
Number of subjects: 301
Study: 12577435

Group type: EXPERIMENTAL
Intervention: Qingwei Zhitong pill (QWZTP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sifangwei tablet
Number of subjects: 120
Study: 9700267

Group type: EXPERIMENTAL
Intervention: tPA (tissue plasminogen activator)
Number of subjects: 0
Study: 1416136

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 20
Study: 3929374

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 0
Study: 30326789

Group type: EXPERIMENTAL
Intervention: Caffeine (∼3 mg/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Expectancy of caffeine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29300752

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27810028

Group type: EXPERIMENTAL
Intervention: Lunge ankle dorsiflexion measurement device (LAD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tester A using LAD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tester B using LAD
Number of subjects: 24
Study: 24152974

Group type: EXPERIMENTAL
Intervention: DelpHi-Intervention conducted by Dementia Care Managers (DCMs) with dementia-specific training; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study: 22467670

Group type: EXPERIMENTAL
Intervention: Isoniazid (pharmacokinetic variability)
Number of subjects: 3382
Study: 19216048

Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behavioral therapy (ICBT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Family‐based cognitive‐behavioral therapy (FCBT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Family‐based education, support and attention (FESA)
Number of subjects: 161